201 related articles for article (PubMed ID: 36503724)
1. Systemic Immune-inflammation Index (SII) During Induction has Higher Predictive Value Than Preoperative SII in Non-muscle-invasive Bladder Cancer Patients Receiving Intravesical Bacillus Calmette -Guerin.
Deng-Xiong L; Qing-Xin Y; De-Chao F; Fa-Cai Z; Rui-Cheng W; Shi X; Han P
Clin Genitourin Cancer; 2023 Jun; 21(3):e145-e152. PubMed ID: 36503724
[TBL] [Abstract][Full Text] [Related]
2. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
[TBL] [Abstract][Full Text] [Related]
3. Predictive Role of the Systemic Immune Inflammation Index for Intravesical BCG Response in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer.
Bolat D; Baltaci S; Akgul M; Karabay E; Izol V; Aslan G; Eskicorapci S; Sahin H; Turkeri L;
Urol Int; 2023; 107(6):617-623. PubMed ID: 36809748
[TBL] [Abstract][Full Text] [Related]
4. Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer.
Liu P; Chen S; Gao X; Liang H; Sun D; Shi B; Zhang Q; Guo H
Front Immunol; 2022; 13():1032907. PubMed ID: 36225922
[TBL] [Abstract][Full Text] [Related]
5. Lymphocyte-to-Monocyte Ratio (LMR) During Induction Is a Better Predictor Than Preoperative LMR in Patients Receiving Intravesical Bacillus Calmette -Guerin for Non-Muscle-Invasive Bladder Cancer.
Li DX; Wang XM; Feng DC; Zhang FC; Wu RC; Shi X; Chen K; Bai Y; Han P
Front Oncol; 2022; 12():937638. PubMed ID: 35903700
[TBL] [Abstract][Full Text] [Related]
6. Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guérin Intravesical Instillation Therapy.
Maeyama R; Ikeda M; Shimura S; Amano N; Murakami Y; Yamada Y; Koguchi D; Tachibana T; Kawamura M; Sakata Y; Hagiwara M; Matsumoto K; Iwamura M
Chemotherapy; 2023; 68(4):190-196. PubMed ID: 35390791
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein as a prognostic predictor for non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guérin therapy: A Japan Urological Oncology Group study analysis.
Nishikawa R; Miyake M; Morizane S; Shimizu R; Teraoka S; Honda M; Iida K; Nishimura N; Sazuka T; Kimura T; Ito A; Shiga K; Taoka R; Kojima T; Kobayashi T; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K; Takenaka A
Int J Urol; 2023 Mar; 30(3):299-307. PubMed ID: 36448522
[TBL] [Abstract][Full Text] [Related]
10. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
[TBL] [Abstract][Full Text] [Related]
11. Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non-muscle-invasive bladder cancer.
Ye K; Xiao M; Li Z; He K; Wang J; Zhu L; Xiong W; Zhong Z; Tang Y
Cancer Med; 2023 Feb; 12(4):4206-4217. PubMed ID: 36214475
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
13. [Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive bladder cancer: outcomes of 421 patients in a single center].
Cai T; Lu J; Lin Z; Lup M; Liang H; Qin Z; Ye Y
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Mar; 43(3):488-494. PubMed ID: 37087596
[TBL] [Abstract][Full Text] [Related]
14. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
[TBL] [Abstract][Full Text] [Related]
15. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
Sfakianos JP; Kim PH; Hakimi AA; Herr HW
J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
[TBL] [Abstract][Full Text] [Related]
16. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
[TBL] [Abstract][Full Text] [Related]
17. Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guérin.
Trépanier G; Nykopp T; Rosebush-Mercier R; Gris T; Fadel J; Black PC; Toren P
Clin Genitourin Cancer; 2024 Apr; 22(2):354-359.e1. PubMed ID: 38185610
[TBL] [Abstract][Full Text] [Related]
18. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.
Lobo N; Hensley PJ; Bree KK; Nogueras-Gonzalez GM; Navai N; Dinney CP; Sylvester RJ; Kamat AM
Eur Urol Oncol; 2022 Feb; 5(1):84-91. PubMed ID: 34920986
[TBL] [Abstract][Full Text] [Related]
19. Predictive Values of Preoperative Prognostic Nutritional Index and Systemic Immune-Inflammation Index for Long-Term Survival in High-Risk Non-Muscle-Invasive Bladder Cancer Patients: A Single-Centre Retrospective Study.
Bi H; Shang Z; Jia C; Wu J; Cui B; Wang Q; Ou T
Cancer Manag Res; 2020; 12():9471-9483. PubMed ID: 33061634
[TBL] [Abstract][Full Text] [Related]
20. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
